SCHEMBL104337

SCHEMBL104337

CC(C)c1ccc(NC(=O)N2CCCC2)cc1

nearest known ligand 0.75

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 8/20 0.75
NPC1 O15118 7/20 0.75
SMN1; SMN2 Q16637 6/20 0.66
KMT2A Q03164 5/20 0.66
MEN1 O00255 1/20 0.66
PANK3 Q9H999 6/20 0.64
CNR2 P34972 1/20 0.63
MAPT P10636 3/20 0.63
TP53 P04637 2/20 0.63
ALDH1A1 P00352 2/20 0.63
THRB P10828 1/20 0.63
MAPK1 P28482 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4559943 0.97 NPC1 (0.75) RAB9ANPC1SMN1; SMN2KMT2AMEN1
SCHEMBL104605 0.87 NPC1 (0.71) RAB9ANPC1SMN1; SMN2KMT2APANK3
SCHEMBL6764523 0.87 NPC1 (0.71) RAB9ANPC1SMN1; SMN2KMT2APANK3
SCHEMBL10253152 0.87 NPC1 (0.63) RAB9ANPC1SMN1; SMN2KMT2AMEN1
SCHEMBL10253430 0.86 CNR2 (0.63) RAB9ANPC1SMN1; SMN2KMT2APANK3
SCHEMBL104586 0.86 RAB9A (1.00) RAB9ANPC1SMN1; SMN2KMT2AMEN1
SCHEMBL14597010 0.86 NPC1 (0.69) RAB9ANPC1SMN1; SMN2KMT2APANK3
SCHEMBL1574988 0.84 NPC1 (0.59) RAB9ANPC1SMN1; SMN2KMT2APANK3
SCHEMBL10253029 0.84 SMN1; SMN2 (0.66) RAB9ANPC1SMN1; SMN2KMT2AMEN1
SCHEMBL1575266 0.83 NPC1 (0.58) RAB9ANPC1SMN1; SMN2KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026098560-A2 BENZENE-CONTAINING POLYCYCLIC DERIVATIVE MODULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF 上海翰森生物医药科技有限公司 2026-05-15 WO disclosed
US-20120059162-A1 FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION ONCOTHERAPY SCIENCE, INC. (JP) 2012-03-08 US disclosed
US-8119808-B2 Tetrahydroquinoline derivatives as cannabinoid receptor modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2012-02-21 US disclosed
US-8119808-B2 Tetrahydroquinoline derivatives as cannabinoid receptor modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2012-02-21 US disclosed
US-20110104315-A1 TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS BRISTOL-MYERS SQUIBB COMPANY 2011-05-05 US disclosed
US-20110104315-A1 TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS BRISTOL-MYERS SQUIBB COMPANY 2011-05-05 US disclosed
US-7884113-B2 Tetrahydroquinoline derivatives as cannabinoid receptor modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2011-02-08 US disclosed
US-20080194625-A1 TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS BRISTOL-MYERS SQUIBB COMPANY 2008-08-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120059162-A1 FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION NR0B1, GRK7, NR5A2 RAB9A 3030/4885NPC1 1892/4885SMN1; SMN2 4581/4885
US-20110104315-A1 TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS CNR2, CNR1, OPRL1 RAB9A 1371/4885NPC1 1136/4885SMN1; SMN2 3460/4885
US-20080194625-A1 TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS CNR2, CNR1, OPRL1 RAB9A 1371/4885NPC1 1136/4885SMN1; SMN2 3460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.